Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials-Reference-Cited by-同舟云学术

Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials

Published:1995-02 Issue:2 Volume:6 Page:141-151
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Chabot G.G.,Abigerges D.,Catimel G.,Culine S.,de Forni M.,Extra J.-M.,Mahjoubi M.,Hérait P.,Armand J.-P.,Bugat R.,Clavel M.,Marty M.E.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/6/2/141/494318/6-2-141.pdf

Reference54 articles.

1. Plant antitumor agents;Wall;I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc,1966

2. Action of camptothecin on mammalian cells in cultures;Li;Cancer Res,1972

3. Lethal activity of camptothecin sodium on human lymphoma cells;Drewinko;Cancer Res,1974

4. Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin;Gallo;J Natl Cancer Inst,1971

5. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC 100880);Gottlieb;Cancer Chemother Rep,1970

Cited by 154 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Population pharmacokinetics of intraperitoneal irinotecan and SN‐38 in patients with peritoneal metastases from colorectal origin;CPT: Pharmacometrics & Systems Pharmacology;2024-04-17

2. Innovative Nanoparticulate Strategies in Colon Cancer Treatment: A Paradigm Shift;AAPS PharmSciTech;2024-03-01

3. Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1;Clinical Pharmacokinetics;2023-09-16

4. Two-Stage SN38 Release from a Core–Shell Nanoparticle Enhances Tumor Deposition and Antitumor Efficacy for Synergistic Combination with Immune Checkpoint Blockade;ACS Nano;2022-11-16

5. Changes in Neutrophil to Lymphocyte Ratio, Lymphocyte to Monocyte Ratio, and Platelet to Lymphocyte Ratio During Palliative Radiotherapy May Predict Efficacy of Immune Checkpoint Inhibitor as Re-Challenge Treatment in Advanced Gastric Cancer: A Case Report;Frontiers in Oncology;2022-05-19